This announcement, sourced from a recent SEC filing, indicates a shift in the company's governance structure as it moves forward with one fewer board member. In other recent news, Corbus Pharmaceuticals has unveiled its Phase 1 clinical study findings of CRB-701, an innovative cancer treatment, at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. The study focuses on CRB-701, an antibody-drug conjugate targeting Nectin-4, and aims to assess its safety, pharmacokinetics, and efficacy in patients with advanced solid tumors. Meanwhile, H.C. Wainwright analyst Andres Y. Maldonado adjusted the price target for Corbus shares to $50, down from $75, while maintaining a Buy rating. This decision followed the presentation of updated data from the Western study of CRB-701, highlighting its favorable risk-benefit profile compared to other nectin-4 ADCs.